Creative Medical Technology Holdings (CELZ) Return on Sales (2017 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Return on Sales of 20.34% for Q1 2026, down 1488.0% year-over-year from 1.47% in Q1 2025, and down 173.67% quarter-over-quarter from 7.43% in Q4 2025.
Creative Medical Technology Holdings (CELZ) Return on Sales (2017 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Return on Sales for 10 consecutive years, with 20.34% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Sales fell 1488.0% year-over-year to 20.34%; the TTM figure through Mar 2026 stood at 20.34% (down 1519.0% YoY), while the FY2025 annual figure was 10.56%, down 455.0% from the prior year.
- Return on Sales fell to 20.34% in Q1 2026 per CELZ's latest filing, from 7.43% in the prior quarter.
- Across five years, Return on Sales topped out at 0.18% in Q3 2022 and bottomed at 20.34% in Q1 2026.
- Historically, Return on Sales has averaged 5.59% across 5 years, with a median of 4.83% in 2024.
- Annual changes were most pronounced in 2025 — Return on Sales jumped 249 bps — and 2026, when it sank 1488 bps.
- Creative Medical Technology Holdings' Return on Sales stood at 3.34% in 2022, then sank by 67 bps to 5.6% in 2023, then plunged by 77 bps to 9.92% in 2024, then climbed by 25 bps to 7.43% in 2025, then tumbled by 174 bps to 20.34% in 2026.
- Business Quant data shows CELZ's Return on Sales at 20.34% in Q1 2026, 7.43% in Q4 2025, and 11.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.00% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.00% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.00% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.00% |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | -24.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.24% |
| Mar 31, 2026 | -20.34% |
| Dec 31, 2025 | -7.43% |
| Sep 30, 2025 | -11.81% |
| Jun 30, 2025 | -11.48% |
| Mar 31, 2025 | -5.46% |
| Dec 31, 2024 | -9.92% |
| Sep 30, 2024 | -4.83% |
| Jun 30, 2024 | -1.95% |
| Mar 31, 2024 | -5.86% |
| Dec 31, 2023 | -5.60% |
| Sep 30, 2023 | -2.42% |
| Jun 30, 2023 | -1.27% |
| Mar 31, 2023 | -1.36% |
| Dec 31, 2022 | -3.34% |
| Sep 30, 2022 | -0.18% |
| Jun 30, 2022 | -0.93% |
| Mar 31, 2022 | -0.77% |
| Dec 31, 2021 | -0.57% |
| Sep 30, 2021 | -1.84% |